We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sensitive Urine Assay Detects Prostate Cancer

By LabMedica International staff writers
Posted on 29 Aug 2011
An innovative prostate screening test has been developed that may be more sensitive in detecting prostate cancer than traditional screening methods. More...


The test provides an original way to look at prostate cancer diagnosis utilizing a novel biological assay, which differentiates prostate-specific antigen's (PSA) molecular structures arising from cancer versus noncancerous glands.

Scientists at Case Western Reserve University School of Medicine collaborating with other institutions, studied a urine-based test that works differently than most prostate screening methods. They used a novel assay to separate PSA protein structures as being linked to either a “cancer” or “noncancer” pathologic diagnosis based on ultrasound-guided biopsy. Instead of attempting to find a single genetic biomarker, which predicts the presence of cancer, the Prostate-specific Antigen/Solvent Interaction Analysis (PSA/SIA) assay is based on the assumption that there may be myriad different ultrastructural changes in the PSA protein, which define the cancer phenotype.

The PSA/SIA assay determined the relative partitioning of heterogeneous PSA isoform populations in urine between two aqueous phases. The initial study, collected at three clinical sites, followed 222 men, and found that the new screening method had 100% sensitivity with no false negative results and 80.3% specificity showing low false positive results. The accuracy of traditional serum PSA is limited by both relatively high false positive and false negative rates. Current diagnostic strategies that use total PSA to determine the need for biopsy demonstrate false positive rates of approximately 55% to 75%.

The PSA/SIA assay, a product of AnalizaDx (Cleveland, OH, USA) provides ratiometric information independently of PSA concentration. In the preliminary study, analysis of the overall structurally heterogeneous PSA isoform population using the SIA assay showed promising results to be further evaluated in future studies. Arnon Chait, PhD, CEO of AnalizaDx, said, "This new assay is a complete departure from how the scientific community has looked at biomarkers for cancer. Instead of just measuring levels of proteins, we are exploring changes in structure which are associated with cancer.” The study was published online on July 22, 2011, in the journal Urology.

Related Links:
Case Western Reserve University School of Medicine
AnalizaDx




Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.